House dust mite allergy immunotherapy - Bial

Drug Profile

House dust mite allergy immunotherapy - Bial

Alternative Names: Allergovac DPT; Allergovac house dust mite; Allergovac house dust mite depot; BIA 15-2957

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator Bial
  • Developer BIAL
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 14 Nov 2016 BIAL Industrial Farmaceutca initiates a phase II trial for Allergic rhinoconjunctivitis in Spain (EudraCT2016-002944-18)
  • 01 Jul 2016 BIAL Industrial Farmacéutica initiates a phase I trial for Allergic rhinoconjunctivitis in Spain (SC) (NCT02881879)
  • 28 Jul 2015 Phase-II development is ongoing in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top